Exploratory imaging outcomes of a phase 1b/2a clinical trial of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: Structural effects and functional connectivity outcomes.

Alzheimers Dement (N Y) · 2022 · PMC8919249 · PMID 35310526

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

Analyses conservatively suggest a numerical trend toward decreased atrophy in ALLO‐treated participants across all doses, with the greatest potential for regeneration in the 4 mg dose group.

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.